{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:03:04Z","timestamp":1785358984127,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijgc.2026.104500","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:46:20Z","timestamp":1769042780000},"page":"104500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world use and outcomes of hyperthermic intra-peritoneal chemotherapy for stage III ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7262-1015","authenticated-orcid":false,"given":"S.","family":"Lot Aronson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby M.","family":"van Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"Algera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lopez-Yurda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike A.","family":"van der Aa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8693-7299","authenticated-orcid":false,"given":"Christianne A.R.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H.J.T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-1994","authenticated-orcid":false,"given":"Willemien J.","family":"van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemien J.","family":"van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik W.R.","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph H.M.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon D.J.M.","family":"van Gent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Roelofsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike A.P.C.","family":"van Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Reesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor D.","family":"de Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrijne","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Roes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.104500_bib1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bpobgyn.2021.06.004","article-title":"Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer","volume":"78","author":"Vos","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104500_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2020.12.029","article-title":"State of the Science: the role of HIPEC in the treatment of ovarian cancer","volume":"160","author":"Dellinger","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104500_bib3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104500_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104500_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejso.2019.05.006","article-title":"Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer","volume":"47","author":"Koole","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104500_bib6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1200\/JCO.19.00594","article-title":"Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in Stage III ovarian cancer on the basis of a randomized Phase III trial","volume":"37","author":"Koole","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104500_bib7","unstructured":"NVOG. Richtlijn Epithelial Ovariumcarcinoom. www.richtlijnendatabase.nl. Accessed date: December 31, 2025."},{"issue":"9453","key":"10.1016\/j.ijgc.2026.104500_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104500_bib9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1177\/1740774506073464","article-title":"Generalizing results of randomized trials to clinical practice: reliability and cautions","volume":"3","author":"Flather","year":"2006","journal-title":"Clin Trials"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104500_bib10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.ejso.2021.01.019","article-title":"Clinical auditing as an instrument to improve care for patients with ovarian cancer: the Dutch Gynecological Oncology Audit (DGOA)","volume":"47","author":"Baldewpersad Tewarie","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ijgc.2026.104500_bib11","article-title":"Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus","volume":"39","author":"van Stein","year":"2022","journal-title":"Gynecol Oncol Rep"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104500_bib12","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1056\/NEJMoa1801109","article-title":"Sodium thiosulfate for protection from cisplatin-induced hearing loss","volume":"378","author":"Brock","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104500_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.ijgc.2026.104500_bib14","series-title":"Flexible Imputation of Missing Data","author":"van Buuren","year":"2018"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104500_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0962280217713032","article-title":"Propensity score analysis with partially observed covariates: how should multiple imputation be used?","volume":"28","author":"Leyrat","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104500_bib16","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/sim.2174","article-title":"Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data","volume":"24","author":"Xie","year":"2005","journal-title":"Stat Med."},{"key":"10.1016\/j.ijgc.2026.104500_bib17","series-title":"Causal Diagrams. Wiley StatsRef: Statistics Reference Online","first-page":"1","author":"Greenland","year":"2017"},{"issue":"14","key":"10.1016\/j.ijgc.2026.104500_bib18","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/sim.7654","article-title":"Bootstrap inference when using multiple imputation","volume":"37","author":"Schomaker","year":"2018","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104500_bib19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104500_bib20","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104500_bib21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"9990","key":"10.1016\/j.ijgc.2026.104500_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104500_bib23","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 17","key":"10.1016\/j.ijgc.2026.104500_bib24","first-page":"LBA5500","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7)","volume":"43","author":"Mahner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104500_bib25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ygyno.2022.02.013","article-title":"Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: a Dutch population-based study using data from the \u2018Dutch Gynecological Oncology Audit","volume":"165","author":"Algera","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104500_bib26","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1002\/cncr.33167","article-title":"Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: a single-center, real-life experience","volume":"126","author":"Ghirardi","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104500_bib27","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamasurg.2023.3944","article-title":"Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy","volume":"158","author":"Lee","year":"2023","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104500_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1245\/s10434-021-10661-3","article-title":"Bowel anastomosis after or before HIPEC: a comparative study in patients undergoing CRS+HIPEC for peritoneal surface malignancy","volume":"29","author":"Somashekhar","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104500_bib29","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104500_bib30","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.24.00686","article-title":"Hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a randomized trial on survival evaluation (HORSE; MITO-18)","volume":"43","author":"Fagotti","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104500_bib31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104500_bib32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ygyno.2016.04.012","article-title":"Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands","volume":"141","author":"Eggink","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104500_bib33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.asjsur.2021.06.003","article-title":"Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis","volume":"45","author":"Chidambarasamy","year":"2022","journal-title":"Asian J Surg"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104500_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2008.11.011","article-title":"Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands","volume":"112","author":"Vernooij","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104500_bib35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","article-title":"Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer","volume":"121","author":"Harter","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104500_bib36","series-title":"HIPEC E-learning","author":"van Stein","year":"2023"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26000320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26000320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:24:07Z","timestamp":1785356647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26000320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1048891X26000320"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104500","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world use and outcomes of hyperthermic intra-peritoneal chemotherapy for stage III ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104500"}}